Edition:
India

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

7.24USD
22 Nov 2017
Change (% chg)

$0.24 (+3.43%)
Prev Close
$7.00
Open
$7.11
Day's High
$7.44
Day's Low
$7.11
Volume
13,847
Avg. Vol
7,165
52-wk High
$10.10
52-wk Low
$4.94

Chart for

About

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-re... (more)

Overall

Beta: --
Market Cap(Mil.): $50.10
Shares Outstanding(Mil.): 9.40
Dividend: --
Yield (%): --

Financials

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

2:59am IST

BRIEF-Leap Therapeutics announces $18 million private placement offering

* Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​

15 Nov 2017

BRIEF-Leap Therapeutics qtrly loss per share $0.73

* Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial

13 Nov 2017

BRIEF-Leap Therapeutics announces collaboration with EORTC

* Leap Therapeutics announces collaboration with EORTC to evaluate DKN-01 in combination with PD-l1 cancer immunotherapy and chemotherapy in esophagogastric and biliary tract cancers

08 Sep 2017

BRIEF-Leap Therapeutics says Q2 loss per share $0.74

* Q2 loss per share $0.74 - SEC filing Source text for Eikon: Further company coverage:

11 Aug 2017

BRIEF-Leap Therapeutics Q2 net loss $6.9 mln vs $7.5 mln, a year earlier

* Leap therapeutics reports second quarter 2017 financial results

11 Aug 2017

BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study

* Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg)

22 Jun 2017

BRIEF-Leap Therapeutics announces collaboration with Merck

* Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer

21 Jun 2017

Earnings vs. Estimates